What is Pacific Biosciences of California's R&D?

Pacific Biosciences of California (PACB) reported R&D of $19.61M in Q1 2026.

How has Pacific Biosciences of California's R&D changed year-over-year?

Pacific Biosciences of California's R&D decreased by 32.5% year-over-year, from $29.05M to $19.61M.

What is the long-term trend for Pacific Biosciences of California's R&D?

Over 4 years (2021 to 2025), Pacific Biosciences of California's R&D has grown at a -3.6% compound annual growth rate (CAGR), from $112.9M to $97.31M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Pacific Biosciences of California PACB R&D

Discontinued — last reported Q1 '26

R&D at other companies

IlluminaILMN

$240M-4.8%

RevvityRVTY

$57.89M+8.0%

Maravai LifeSciences Holdings, Inc.MRVI

$3.89M-20.4%

Agilent TechnologiesA

$126M+12.5%

Thermo Fisher ScientificTMO

$336M-1.8%

Twist Bioscience CorporationTWST

$19.7M-17.7%

Segments

By segment

See full

Reportable Segment$19.61M-32.5%

Other financials

Income statement

See full

Revenue$37.2M+0.1%

Gross profit$12.8M+1,037%

Operating income-$8.4M+98.1%

Net income-$8.3M+98.1%

EPS (diluted)-$0.03+97.9%

Balance sheet

See full

Cash & equivalents$57.9M-4.7%

Total debt$59.3M+12.1%

Total equity$2.4M-97.4%

Total assets$782.4M-9.1%

Cash flow

See full

Operating cash flow-$44.7M-1.4%

CapEx$3.0M+119%

Free cash flow-$47.7M-5.0%

Valuation

See full

Market cap$496.96M+30.4%

Enterprise value$498.38M+33.5%

P/S3.1×+0.6×

Profitability

See full

Gross margin37.5%+21.3pp

Operating margin-83.3%-38.2pp

Net margin-80.3%-36.1pp

FCF margin-72.6%-20.0pp

Returns & leverage

See full

Return on equity-273.6%+314pp

Debt / equity25.1×+24.5×

Current ratio5.7×-1.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacific Biosciences of California's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Pacific Biosciences of California's R&D?: Pacific Biosciences of California (PACB) reported R&D of $19.61M in Q1 2026.
How has Pacific Biosciences of California's R&D changed year-over-year?: Pacific Biosciences of California's R&D decreased by 32.5% year-over-year, from $29.05M to $19.61M.
What is the long-term trend for Pacific Biosciences of California's R&D?: Over 4 years (2021 to 2025), Pacific Biosciences of California's R&D has grown at a -3.6% compound annual growth rate (CAGR), from $112.9M to $97.31M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.